Press Releases

Prior announcements are available on the ASX website.

December 9, 2016
ResApp Initiates SMARTCOUGH-C Study Evaluating Efficacy of ResAppDx for Diagnosing Childhood Respiratory Disease

November 28, 2016
ResApp to Present at Wilsons Healthcare IT Conference

November 16, 2016
ResApp Receives Institutional Review Board Approval at Texas Children’s Hospital for SMARTCOUGH-C Study

November 11, 2016
ResApp Receives Institutional Review Board Approval at Massachusetts General Hospital for SMARTCOUGH-C Study

October 25, 2016
ResApp Receives Australian Emerging Company of the Year Award at the “Johnson & Johnson Innovation Industry Excellence Awards”

October 21, 2016
ResApp Receives First Institutional Review Board Approval for SMARTCOUGH-C Study

October 12, 2016
ResApp Wins Innovation Excellence Award at Tech23 2016

October 3, 2016
ResApp Announces Further Positive Results from Adult Clinical Study

September 15, 2016
ResApp Begins Field Evaluation with Leading Global Humanitarian Organisation

August 19, 2016
ResApp Wins Global Grand Finals at the 2016 Talent Unleashed Awards

August 18, 2016
ResApp Expands Diagnostic Application to the Management of Respiratory Disease

July 22, 2016
ResApp Wins Category at the 2016 Talent Unleashed Awards

July 20, 2016
ResApp Announces Massachusetts General Hospital as First US Clinical Study Site

June 30, 2016
ResApp Provides Update on US Clinical Study

June 21, 2016
ResApp Announces Positive Preliminary Results from Adult Clinical Study

June 7, 2016
ResApp Provides Australian Adult Study Enrolment Update

April 20, 2016
ResApp Completes Oversubscribed $12.5 Million Capital Raising to Expand Market Opportunity

March 31, 2016
ResApp Provides Updated Paediatric Clinical Study Results

March 14, 2016
ResApp Completes Successful Pre-Submission Meeting with the US FDA

March 7, 2016
ResApp Collaborates with Leading Humanitarian Organisation to Field Test ResApp’s Smartphone-Based Pneumonia Diagnostic in the Developing World

March 2, 2016
ResApp Achieves Breakthrough Performance in Paediatric Clinical Study

February 26, 2016
Second Site Added to Adult Clinical Study

January 22, 2016
ResApp to Exhibit at the McKinsey Future of Digital Healthcare Conference in Dubai

Brian Leedman
Executive Director and VP, Corporate Affairs
+61 412 281 780
ResApp Logo White

ResApp Health Limited
ABN 51 094 468 318
Headquarters: Level 8, 127 Creek St, Brisbane, QLD 4000
Registered Office: Level 24, 44 St Georges Tce, Perth, WA 6000

© 2017 ResApp Health Limited. All Rights Reserved.


+61 8 6211 5099
+61 8 9218 8875
General Information
Clinical Studies
Investor Relations



Terms of Use
Privacy Policy

ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States.

In the United States, ResAppDx is an investigational device and is not available for sale.